THE EFFECT OF BETA-BLOCKERS ON FACTORS OF FIBROSIS IN PATIENTS WITH CHRONIC HEART FAILURE ISCHEMIC HEART DISEASE COMBINED WITH DIABETES MELLITUS TYPE 2 Narizhna A. V., Zalubovska O. I.

Kharkiv National Medical University, Kharkiv, Ukraine

Introduction: according to the world literature of chronic heart failure (CHF) has a high percentage among population, and the mortality rate of patients with this pathology reaches ~ 20% in ischemic heart disease (IHD). An aggravating factor in this pathology plays a concomitant diabetes mellitus (DM) type 2.

Goal: the aim of the study is to evaluate the effectiveness as carvedilol and nebulae on profpolisci markers in patients with CHF with ischemic heart disease combined with type 2 diabetes.

Materials: the study included 106 patients with CHF II – III functional class (FC) as a consequence of CHD, were treated at the cardiology Department of KZOZ "27 city clinical hospital" of CHC (mean age $65,13\pm8.66$ years). The first group included 63 patients with CHF with type 2 diabetes, the second group – 42 patients with CHF in CHD without type 2 diabetes. From the study were excluded patients with acute coronary syndrome, acute myocardial infarction. Of the patients with CHF II FC had 70 patients, FC III – 36 patients. Among patients of the 1st group FC II CHF was diagnosed in 28 patients, III FC – 13. Patients 2 groups with CHF II FC determined in 42 patients, FC III – 23 patients.

The performance factor of fibrosis chemoattractants monocyte protein-1 (MCP-1) were determined by ELISA.

It is known that type 2 diabetes, and related disorders, shows significantly adverse influence on the course of CHF.

Results: in CKD patients with coronary artery disease in the presence of type 2 diabetes is defined by high activity factor of fibrosis MCP-1 simultaneously to the growth of FC. The use of beta-blockers in standard therapy in the treatment of patients with CHF and type 2 diabetes notes a decrease in profpolisci activity as carvedilol and nebulae. However, a significant decrease of MCP-1 runano to the FC celebrates with the involvement carvedilol.